Table 1 Baseline patient characteristics
C1 – Niraparib (n = 25) | C2 – Niraparib + Dostarlimab (n = 22) | ||
|---|---|---|---|
Age | Median (range) | 69 (53–80) | 64.5 (38–80) |
ECOG status | 0 | 5 (20%) | 2 (9%) |
1 | 19 (76%) | 18 (82%) | |
2 | 1 (4%) | 2 (9%) | |
Histology | Serous | 15 (60%) | 9 (41%) |
Endometrioid grade 1 | 3 (12%) | 3 (14%) | |
Endometrioid grade 2 | 3 (12%) | 2 (9%) | |
Endometrioid grade 3 | 3 (12%) | 7 (32%) | |
Mixed serous and endometrioid | 1 (4%) | 1 (5%) | |
Molecular characteristics | MMR deficient | 4 (16%) | 3 (14%) |
p53 abnormal or overexpressed | 15 (60%) | 12 (55%) | |
POLE mutant | 0 | 1 (5%) | |
Prior Regimens | 1 | 8 (32%) | 6 (27%) |
2 | 9 (36%) | 6 (27%) | |
3 | 2 (8%) | 5 (23%) | |
4 | 6 (24%) | 3 (14%) | |
5 | 0 | 1 (5%) | |
6 | 0 | 1 (5%) | |
Number of prior regimens | Median (range) | 2 (1–4) | 2 (1–6) |
Prior Therapya | Systemic platinum chemotherapy | 25 (100%) | 22 (100%) |
Radiation | 18 (72%) | 19 (86%) | |
Surgery | 21 (84%) | 22 (100%) | |
Platinum sensitivityb | Platinum Resistant | 19 (76%) | 15 (68%) |
Platinum Sensitive | 6 (24%) | 7 (32%) |
